Wedbush downgraded Y-mAbs Therapeutics (YMAB) to Neutral from Outperform with an $8.60 price target after SERB Pharmaceuticals agreed to acquire Y-mAbs for $8.60 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB: